Clinical trials
Phase 4 Lymphoma, Large B-Cell, Diffuse trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 5 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mingzhi Zhang | 3 |
| Chongqing University Cancer Hospital | 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 1 |
| Millennium Pharmaceuticals, Inc. | 1 |
| PETHEMA Foundation | 1 |
| Ruijin Hospital | 1 |
| The First Hospital of Jilin University | 1 |
| University of Maryland, Baltimore | 1 |
| Vanderbilt-Ingram Cancer Center | 1 |
| Zhengzhou University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Large B-Cell, Diffuse | 12 |
| Recurrence | 3 |
| Burkitt Lymphoma | 2 |
| Hodgkin Disease | 2 |
| Lymphoma | 2 |
| Anemia | 1 |
| Blast Crisis | 1 |
| Dendritic Cell Sarcoma, Interdigitating | 1 |
| Graft vs Host Disease | 1 |
| HIV Infections | 1 |
Trials
Showing 51 to 12 of 12. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.